Stranica je namijenjena samo zdravstvenim radnicima u Republici Hrvatskoj.

Search

Menu

Close

PrijavaOdjava
Naši lijekoviTerapijska područjaMedia CentarMedia CentarDogađanjaMaterijaliVideo resursiKontaktirajte nasPovežimo seKontaktirajte nasMedicinske informacije tvrtke Pfizer

Informacije o prijavljivanju nuspojava mogu se pronaći na dnu stranice.

Menu

Close

About Prevenar 20™ at a Glance Serotype Coverage Pneumococcal Disease Clinical Programme RecommendationsPractical Use Resources
Practical use of Prevenar 20™ (Pneumococcal 20-valent Conjugate Vaccine)Prevenar 20™ is administered the same way as Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine)1,2 Similarities shared by Prevenar* vaccines simplify transition to a higher-valent pneumococcal conjugate vaccine (PCV)1,2

Prevenar 20™ uses the same syringe as Prevenar 13®, with a different colour finger grip.

Prevenar includes Prevenar 13® and Prevenar 20TM. For paediatric use in [Country], Prevenar 13® has been available since 2010 and Prevenar 20TM since 2023.1,2,5
Simple steps for syringe preparation
Prevenar 20™ can be coadministered with the [Local body]-recommended infant immunisation schedule.1,3
Storage and handling for Prevenar 20™
  • With the approval of the paediatric indication(s), the Apexxnar® name has changed to Prevenar 20™
  • [Local body] permits Apexxnar® packaged products to be used for all Prevenar 20™ indicated age groups [with accompanying leaflet]
  • Dosing and administration remain the same for both products

Please refer to the Prevenar 20™ Summary of Product Characteristics for full dosing and administration recommendations.

Stability data indicate that the vaccine is stable for 96 hours when stored at temperatures from 8°C to 25°C, or 72 hours when stored at temperatures from 0°C to 2°C. At the end of these time periods, Prevenar 20™ should be used or discarded. These data are intended to guide healthcare professionals in case of temporary temperature excursion only.1References:Prevenar 20™ (Pneumococcal 20-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2024.Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2014.Centers for Disease Control and Prevention. ACIP updates: recommendations for the use of 20-valent pneumococcal conjugate vaccine in children—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(39):1072. https://stacks.cdc.gov/view/cdc/133252.Vaxneuvance™ (Pneumococcal 15-valent Conjugate Vaccine). Summary of Product Characteristics. Merck Sharp & Dohme Corp.; 2023.Local approval dates. The broadest serotype coverage for babies in a pneumococcal conjugate vaccine1,2,4 Learn more Loading
PP-PNR-GLB-0425 March 2024

Ako želite prijaviti štetni događaj, molimo Vas pošaljite e-mail na adresu [email protected] ili nazovite broj 013908788. Za medicinske upite, molimo Vas pošaljite e-mail na adresu: [email protected] ili nazovite broj 013908777.

PfizerPro računPfizerPro račun

Za pristup daljnjim materijalima, resursima i primanje obavijesti o lijekovima i cjepivima tvrtke Pfizer

PrijavaRegistracijaRačunOdjava

SAMO ZA ZDRAVSTVENE RADNIKE

Stranica je namijenjena samo zdravstvenim radnicima u Republici Hrvatskoj. Ako ste član šire javnosti koji želi ostvariti pristup informacijama o određenom lijeku, molimo Vas obratite se Vašem liječniku ili ljekarniku. 

Ovu web stranicu Vam donosi Pfizer Croatia d.o.o.

Autorsko pravo 2022. Pfizer Croatia d.o.o. Sva prava pridržana.

PP-UNP-HRV-0139, datum izrade: kolovoz, 2023.
Napuštate PfizerPro
​
Sada napuštate internetsku stranicu kojom upravlja Pfizer. Poveznice koje vode svim vanjskim stranicama su dani kao resurs za naše posjetitelje. Pfizer ne prihvaća nikakvu odgovornost za sadržaj stranica koji nisu u vlasništvu i kojima Pfizer ne upravlja.

PP-UNP-HRV-0139
datum izrade: kolovoz, 2023.
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​ Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​